Gaucher Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years old or older.
- You must be able to understand what the study involves, be willing to follow its requirements, and sign a consent form agreeing to take part.
- You must have Gaucher disease and be considered healthy enough to participate, in the opinion of the study doctor.
- If you are on a specific enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for Gaucher disease, you must have been on the same treatment at the same dose for at least 2 years — or you must not have had any such treatment for at least 2 years.
- If you have Type 1 Gaucher disease and recently changed your dose or switched to a different medication, you may still be able to join if at least 6 months have passed since that change and your doctor considers you stable.
- You must not have taken the supplements coenzyme Q-10, vitamin C, or vitamin E for at least 3 weeks before joining the study.
Who may not be able to join:
- You may not be able to join if you have an unstable medical condition, as judged by the study doctors.
- You may not be able to join if you have another illness or situation that the study doctor believes could put you at risk or affect the quality of the study.
- You may not be able to join if you are pregnant, breastfeeding, or could become pregnant and are not using an accepted form of contraception.
- You may not be able to join if you currently have asthma that requires treatment.
- You may not be able to join if you are unable or unwilling to have blood drawn.
- You may not be able to join if you are unable or unwilling to follow the study schedule and requirements for any reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Reena Kartha, PhD, University of Minnesota
Phone: 612-626-2436
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Plasma C5a Concentration; Change in Plasma Hepcidin Concentration
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.